摘要
目的对英夫利昔单抗治疗关节炎合并乙型肝炎病毒(hepatitis B virus,HBV)感染的肝脏安全性进行评价。方法收集本院近2年收治的45例使用英夫利昔单抗关节炎患者的临床资料,其中15例合并HBV感染。分析其肝功能异常发生率、HBV活动情况及抗病毒治疗情况。选取35例同期未使用英夫利昔单抗的关节炎患者作为对照。结果治疗组15例HBV感染患者中有2例(2/15,13%)出现肝功能异常,3例(3/15,20%)出现HBV DNA升高,与治疗组中非HBV感染患者相比差异有统计学意义(P<0.05),与对照组相比差异无统计学意义(P>0.05)。上述患者给予护肝及抗病毒治疗后肝功能恢复正常,HBV DNA明显下降。预防性抗病毒治疗患者HBV DNA升高发生率为1/6例(17%),较未预防性抗病毒治疗患者低。结论 HBV感染患者使用英夫利昔单抗应注意肝脏安全性,需要密切监测肝功能及HBV DNA,必要时预防性抗病毒治疗。
Objective To evaluate the safety of infliximab in the treatment of arthritis complicated with chronic hepatitis B virus（HBV） infection. Methods Forty-five patients with arthritis treated with infliximab were retrospectively studied, in which 15 patients were infected with HBV. Thirty-five patients who were not treated with infliximab served as controls. Results Fifteen HBV infected patients were treated with infliximab, 2 （13%） of them had liver function abnormalities, 3（20% ） of them had elevated induction of HBV DNA copies. There was significant difference when compared with patients who did not have HBV infection. These patients received anti-viral therapy, and their liver function returned to normal and their HBV DNA copies were decreased. One （ 17% ） patient received prophylactic anti-viral treatment also had elevated HBV DNA copies. Conclusions Special attention should be paid to the liver function changes of patients who are treated with infliximab and complicated with chronic hepatitis B infection. However, all patients should he monitored for liver function and HBV DNA copies changes, and receive anti-viral therapy if necessary.
出处
《中华临床免疫和变态反应杂志》
2012年第1期30-33,共4页
Chinese Journal of Allergy & Clinical Immunology
